Table of Contents
ISRN Ophthalmology
Volume 2014, Article ID 417603, 6 pages
Clinical Study

Phacoemulsification Surgery in Eyes with Neovascular Age-Related Macular Degeneration

1Department of Ophthalmology, Wirral University Teaching Hospital, Arrowe Park Road, Wirral, Merseyside CH49 5PE, UK
2Department of Ophthalmology, St. Paul’s Eye Unit, Royal Liverpool University Hospital, Prescot Street, Liverpool, Merseyside L7 8XP, UK
3Department of Mathematics, University of Leicester, University Road, Leicester LE1 7RH, UK
4The Insurance Unit, Faculty of Economics, Management and Accountancy, University of Malta, Msida, MSD2080, Malta

Received 19 August 2013; Accepted 22 October 2013; Published 22 January 2014

Academic Editors: A. Kakehashi and T. Yasukawa

Copyright © 2014 Andre Grixti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. To evaluate the visual outcomes and effect of phacoemulsification surgery on the progression of neovascular age-related macular degeneration (AMD). Methods. Retrospective, noncomparative, and interventional case series. Thirty eyes from 29 subjects with neovascular AMD treated with intravitreal antivascular endothelial growth factor (VEGF) injections who underwent phacoemulsification and had a postsurgery follow-up of 6 months were included. LogMAR best corrected visual acuity (BCVA) was assessed preoperatively; 1 month, 3 months, and 6 months postoperatively; and finally at the last visit. The frequency of anti-VEGF therapy, calculated as the number of intravitreal injections per month, and central macular thickness (CMT) before and after cataract surgery were determined. Results. Median (range) logMAR BCVA was 0.69 (0.16 to 1.32) preoperatively; 0.55 (−0.04 to 1.32) at 1 month, 0.52 (−0.1 to 1.32) at 3 months, and 0.50 (0.0 to 1.32) at 6 months postoperatively; and 0.6 (0.0 to 1.4) at final visit ( ). There was no difference in the frequency of anti-VEGF injections between the immediate 6 months before and after phacoemulsification, which was equal to 0.1667 injections per month ( ). Median CMT measured 203 μm preoperatively, which temporarily increased to 238 μm at 1 month after surgery ( ) and then spontaneously returned to baseline, measuring 212.5 μm at 3 months postoperatively ( ). Conclusion. Phacoemulsification surgery significantly improved vision in patients with neovascular AMD, with no increased need for anti-VEGF injections to keep the macula dry postoperatively.